{
    "clinical_study": {
        "@rank": "156370", 
        "acronym": "VIP-E", 
        "arm_group": {
            "arm_group_label": "Single-Arm, open-label extension trial", 
            "arm_group_type": "Other", 
            "description": "Single-arm, open label extenstion trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks."
        }, 
        "brief_summary": {
            "textblock": "VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over\n      subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is\n      sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers.\n      VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams,\n      blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab\n      injections following FDA-approved psoriasis treatment regimen."
        }, 
        "brief_title": "Vascular Inflammation in Psoriasis - Extension Study", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Psoriasis", 
            "Cardiovascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Inflammation", 
                "Psoriasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females 18 years of age and older.\n\n          2. Subject completed the 12week VIP Study\n\n          3. Subject willing and able to avoid prolonged exposure of skin affected by psoriasis to\n             natural or sunlight or tanning beds during the course of the study\n\n          4. Subject is willing and able to avoid topical or systemic prescription treatments for\n             psoriasis besides adalimumab during the course of the study\n\n          5. Women are eligible to participate in the study if they meet one of the following\n             criteria:\n\n               1. Women of childbearing potential who are willing to undergo regular pregnancy\n                  testing and agree to use two methods of contraception throughout the study are\n                  eligible to participate\n\n               2. Women who are postmenopausal (for at least one year), sterile, or\n                  hysterectomized are eligible to participate\n\n               3. Women who have undergone tubal ligation and agree to use a second form of\n                  contraception are eligible to participate.\n\n               4. Women who agree to be sexually abstinent, defined as total abstinence from\n                  sexual intercourse, as a form of contraception are eligible to participate in\n                  the study.\n\n          6. Subject is judged to be in good general health as determined by the Principal\n             Investigator based upon the results of medical history, laboratory profile, and\n             physical examination.\n\n          7. Able and willing to give written informed consent and to comply with requirements of\n             this study protocol.\n\n        Exclusion Criteria:\n\n          1. Previous adverse event following exposure to a TNF-alpha antagonist that led to\n             discontinuation of the TNF inihibitor and contraindicates future treatment.\n\n          2. Previous lack of response to a TNF-alpha antagonist led to discontinuation.\n\n          3. Diagnosis of erythrodermic psoriasis, generalized pustular psoriasis, or\n             medication-induced or medication-exacerbated psoriasis.\n\n          4. Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or\n             viral) that may interfere with evaluation of psoriasis.\n\n          5. Subject is taking or requires oral or injectable corticosteroids during the study.\n             Inhaled corticosteroids for stable medical conditions are allowed.\n\n          6. Poorly controlled medical condition, such as unstable ischemic heart disease,\n             congestive heart failure, recent cerebrovascular accidents, psychiatric disease\n             requiring frequent hospitalization, and any other condition, which, in the opinion of\n             the Investigator, would put the subject at risk by participation in the study.\n\n          7. History of diabetes mellitus, type 1 or type 2 (patients with type 2 diabetes may be\n             enrolled if the duration of diabetes is <10 years and HbA1c is <7.0%)\n\n          8. Uncontrolled hypertension, with measured systolic blood pressure >180 mmHg or\n             diastolic blood pressure >90 mmHg\n\n          9. History of demyelinating diseases or lupus.\n\n         10. Subject has infection or risk factors for severe infections, for example:\n\n               -  Known  history of HIV, hepatitis B or C, or other severe, recurrent, or\n                  persistent infections;\n\n               -  Excessive immunosuppression or other factors associated with it, including human\n                  immunodeficiency virus infection;\n\n               -  Active tuberculosis (TB) disease;\n\n               -  Evidence of latent TB infection demonstrated by Purified Protein Derivative\n                  (PPD) \u2265 5 mm of induration or positive Quantiferon-GOLD results as determined\n                  within 6 months of the baseline visit for VIP-E; except if prophylactic\n                  treatment for TB, as recommended by local guidelines, is initiated prior to\n                  administration of study drug or if there is documentation that the subject has\n                  received prophylactic treatment for TB previously.\n\n               -  Any other significant infection requiring hospitalization or intravenous (IV)\n                  antibiotics in the month prior to Baseline;\n\n               -  Infection requiring treatment with oral or parenteral antibiotics within 14 days\n                  prior to Baseline;\n\n               -  Subject will require a live vaccination during study participation including up\n                  to 30 days after the last dose of study drug.\n\n         11. Subject has history of hematological or solid malignancy within the past five years\n             other than successfully treated basal cell carcinoma, non-metastatic cutaneous\n             squamous cell carcinoma or cervical carcinoma in situ.\n\n         12. Female subject who is pregnant or breast-feeding or considering becoming pregnant\n             during the study.\n\n         13. Clinic laboratory analyses showing any of the following abnormal results:\n\n               -  Hemoglobin (Hgb) < 10 g/dL in females or <12 g/dL in males;\n\n               -  White blood cell (WBC) count <2.5 x 109/L\n\n                    -  Subject can be included if WBC count is <2.5 x x 109/L and absolute\n                       neutrophil count (ANC) is >1000 cells / mm3.\n\n               -  WBC count > 15 x 109/L;\n\n               -  Platelet count < 100 x 109/L;\n\n               -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) >2.5 upper\n                  limits of normal (ULN);\n\n               -  Serum total bilirubin \u22652 mg/dL (\u226526 \u00b5mol/L)\n\n         14. Recent history of substance abuse or psychiatric illness that could preclude\n             compliance with the protocol.\n\n         15. If subject is on cholesterol-lowering medication (e.g. statin), dose and form of\n             medication must be stable for 90 days prior to baseline and remain stable throughout\n             the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866592", 
            "org_study_id": "817552"
        }, 
        "intervention": {
            "arm_group_label": "Single-Arm, open-label extension trial", 
            "description": "Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira):  an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.", 
            "intervention_name": "Adalimumab", 
            "intervention_type": "Drug", 
            "other_name": "Humira"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Psoriasis", 
            "Cardiovascular Disease", 
            "Vascular Inflamation", 
            "Lipid Biomarkers", 
            "Metabolic biomarkers", 
            "FDG-PET/CT"
        ], 
        "lastchanged_date": "May 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "victoria.wells@ucdmc.ucdavis.edu", 
                    "last_name": "Victoria Welss", 
                    "phone": "916-734-1267"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95816"
                    }, 
                    "name": "University of California, Davis Health System"
                }, 
                "investigator": {
                    "last_name": "April Armstrong, MD MPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chiah@nhlbi.nih.gov", 
                    "last_name": "Amy Chi"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "National Heart, Lung, and Blood Institute"
                }, 
                "investigator": {
                    "last_name": "Nehal N Mehta, MD MSCE FAHA", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jshand@buffalomedicalgroup.com", 
                    "last_name": "Judith Shand", 
                    "phone": "716-630-1491"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14221"
                    }, 
                    "name": "Buffalo Medical Group"
                }, 
                "investigator": {
                    "last_name": "Robert E Kalb, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "suzette.baezvanderbeek@uphs.upenn.edu", 
                    "last_name": "Suzette Baez VanderBeek, MPH", 
                    "phone": "215-662-3514"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Joel M Gelfand, MD MSCE", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sasha.hamel@hsc.utah.edu", 
                    "last_name": "Sasha Hamel", 
                    "phone": "801-213-2726"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah"
                }, 
                "investigator": {
                    "last_name": "Kristina Callis Duffin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Vascular Inflammation in Psoriasis - Extension Study", 
        "overall_contact": {
            "email": "suzette.baezvanderbeek@uphs.upenn.edu", 
            "last_name": "Suzette Baez VanderBeek, MPH", 
            "phone": "215-662-3514"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Joel M Gelfand, MD MSCE", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change in total vascular inflammation of five aortic segments as assessed on FDG-PET/CT between week 52 of the adalimumab treatment period and baseline and/or week 12 scans from the VIP trial.", 
                "measure": "Vascular Inflammation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "description": "Change in metabolic, lipid, and inflammatory biomarker levels between week 52 of the adalimumab treatment period and baseline and/or week 12 assessments from the VIP trial.", 
                "measure": "Cardiometabolic Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline - Week 52"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety will be assessed by evaluating all subject reported adverse events through the duration of the study.", 
                "measure": "Safety/Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "All visits through 52 week study"
            }, 
            {
                "description": "Patient reported quality of life outcomes will be assessed using the following standard instruments:  EuroQol EQ-5D, Dermatology Life Quality Index (DLQI), MEDFICTS dietary assessment instrument, International Physical Activity Questionnaire (IPAQ), and Multidimensional Health Assessment Questionnaire (MDHAQ).", 
                "measure": "Patient-Reported Quality of Life Outcomes", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 10, 12, 20.22, 30,32,40,42, 52."
            }
        ], 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "collaborator": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}